{"id":"tuberculosis-treatment","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Peripheral neuropathy"},{"rate":"5-10%","effect":"Hepatotoxicity"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Gastrointestinal upset"}]},"_chembl":{"chemblId":"CHEMBL218650","moleculeType":"Small molecule","molecularWeight":"534.49"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Isoniazid is a prodrug that is activated by the enzyme catalase-peroxidase in M. tuberculosis. Once activated, it inhibits the enzyme enoyl-acyl carrier protein reductase (InhA), which is essential for the synthesis of mycolic acid. This leads to the accumulation of mycolic acid precursors and the inhibition of bacterial growth and replication.","oneSentence":"Isoniazid works by inhibiting the synthesis of mycolic acid in Mycobacterium tuberculosis, thereby inhibiting bacterial growth and replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:02.924Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of tuberculosis"},{"name":"Prophylaxis of tuberculosis"}]},"trialDetails":[{"nctId":"NCT07164742","phase":"NA","title":"Parent Study Name: Pulmonary Rehabilitation to Reduce Post-Tuberculosis Morbidity (TB Pure)","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-03-18","conditions":"TB - Tuberculosis, TB, TB Infection","enrollment":690},{"nctId":"NCT04930744","phase":"PHASE2","title":"Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2021-08-26","conditions":"Tuberculosis, Pulmonary Tuberculosis, HIV Coinfection","enrollment":112},{"nctId":"NCT06593080","phase":"NA","title":"The DECIDE-TB Trial; Validation of Treatment Decision Algorithms for Childhood Tuberculosis","status":"RECRUITING","sponsor":"Chishala Chabala","startDate":"2024-06-01","conditions":"Tuberculosis, Child Health, HIV","enrollment":30240},{"nctId":"NCT05586230","phase":"PHASE1","title":"Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-03","conditions":"Tuberculosis, Rifampicin Resistant Tuberculosis","enrollment":72},{"nctId":"NCT07485868","phase":"","title":"Development of a Clinical-epidemiological Score Predictive of Tuberculosis.","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2026-04-01","conditions":"Tuberculosis","enrollment":686},{"nctId":"NCT07486024","phase":"PHASE3","title":"Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR)","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-04","conditions":"MDR-TB, Tuberculosis Multi Drug Resistant Active, Antibiotic Resistance","enrollment":55},{"nctId":"NCT05917210","phase":"NA","title":"Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda","status":"RECRUITING","sponsor":"Yale University","startDate":"2026-03-16","conditions":"Tuberculosis, HIV","enrollment":1920},{"nctId":"NCT07484490","phase":"NA","title":"Effects of the Active Cycle of Breathing Technique With and Without Balloon Blowing Therapy in Tuberculosis","status":"RECRUITING","sponsor":"Riphah International University","startDate":"2026-01-29","conditions":"Tuberculosis","enrollment":34},{"nctId":"NCT05994742","phase":"PHASE3","title":"An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Queen Mary University of London","startDate":"2024-07-15","conditions":"Severe Acute Malnutrition, HIV, Comorbidities and Coexisting Conditions","enrollment":674},{"nctId":"NCT06192160","phase":"PHASE2","title":"Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-03-11","conditions":"Pulmonary Tuberculosis","enrollment":315},{"nctId":"NCT07479030","phase":"NA","title":"A Home-Based Approach to Tuberculosis Preventive Treatment Management","status":"NOT_YET_RECRUITING","sponsor":"Dilla University","startDate":"2026-04-15","conditions":"Tuberculosis","enrollment":1300},{"nctId":"NCT03057756","phase":"","title":"Treatment of Tuberculosis Multidrug Resistance Treatment of Tuberculosis Multidrug Resistance","status":"COMPLETED","sponsor":"Centre de Recherche Médicale de Lambaréné","startDate":"2015-09-11","conditions":"Multi-drug Resistant Tuberculosis","enrollment":23},{"nctId":"NCT07477119","phase":"PHASE4","title":"Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment","status":"NOT_YET_RECRUITING","sponsor":"Marco Schiuma","startDate":"2026-03","conditions":"Linezolid, Tuberculosis Multi Drug Resistant Active, Therapeutic Drug Monitoring (TDM)","enrollment":150},{"nctId":"NCT07472348","phase":"","title":"Isoniazid-Related Hepatotoxicity in Clinical Practice: Incidence and Predictors","status":"NOT_YET_RECRUITING","sponsor":"ASST Fatebenefratelli Sacco","startDate":"2026-05-30","conditions":"Tuberculosis Infection, Tuberculosis Infection, Latent","enrollment":220},{"nctId":"NCT07467252","phase":"PHASE2","title":"AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT","status":"NOT_YET_RECRUITING","sponsor":"Ministry of Health, Saudi Arabia","startDate":"2026-09","conditions":"Pulmonary Tuberculosis","enrollment":200},{"nctId":"NCT06050356","phase":"PHASE1","title":"First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b","status":"ACTIVE_NOT_RECRUITING","sponsor":"Statens Serum Institut","startDate":"2024-03-14","conditions":"Healthy","enrollment":140},{"nctId":"NCT05730283","phase":"PHASE2","title":"Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin","status":"RECRUITING","sponsor":"Kevin Winthrop","startDate":"2025-06-02","conditions":"Ototoxicity, Drug-Induced","enrollment":105},{"nctId":"NCT04230395","phase":"NA","title":"Alcohol Reduction Among People With TB and HIV in India","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2022-09-22","conditions":"Tuberculosis, HIV","enrollment":450},{"nctId":"NCT02354014","phase":"PHASE2","title":"Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2016-05-03","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":60},{"nctId":"NCT04701151","phase":"PHASE4","title":"NORTH-REG Dwell-Time Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jørgen Bjerggaard Jensen","startDate":"2021-02-03","conditions":"Side Effect of Drug","enrollment":314},{"nctId":"NCT05538663","phase":"PHASE3","title":"Intravesical BCG vs GEMDOCE in NMIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-02-07","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":870},{"nctId":"NCT07422870","phase":"","title":"GRAnulomatous MAstitis REGistry Study","status":"NOT_YET_RECRUITING","sponsor":"European Breast Cancer Research Association of Surgical Trialists","startDate":"2026-04-01","conditions":"Idiopathic Granulomatous Mastitis, Granulomatous Mastitis","enrollment":1000},{"nctId":"NCT07440160","phase":"NA","title":"Digitally Facilitated, Integrated Community and Facility-Based Interventions: The HEART-TB Trial Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arba Minch University","startDate":"2025-07-01","conditions":"Tuberculosis","enrollment":278},{"nctId":"NCT07436104","phase":"PHASE4","title":"Mortality Control Program for Economically Productive Age Group in Tribal Area of Melghat.","status":"COMPLETED","sponsor":"MAHAN Trust","startDate":"2004-01-01","conditions":"Hypertension (HTN), Diarrhea, Pneumonia","enrollment":72564},{"nctId":"NCT03512249","phase":"PHASE2","title":"Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence","status":"COMPLETED","sponsor":"International AIDS Vaccine Initiative","startDate":"2019-01-31","conditions":"Tuberculosis, Pulmonary","enrollment":831},{"nctId":"NCT05556746","phase":"PHASE2","title":"Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-11-24","conditions":"Tuberculosis, Pulmonary, HIV","enrollment":94},{"nctId":"NCT06728930","phase":"","title":"Evaluation of a Novel Microbiological Diagnostic Test for Latent Mycobacterium Tuberculosis Infection","status":"ENROLLING_BY_INVITATION","sponsor":"Queen Mary University of London","startDate":"2024-04-02","conditions":"Latent Tuberculosis Infection, Tuberculosis Infection, Latent","enrollment":250},{"nctId":"NCT07419568","phase":"NA","title":"Burden of Tuberculosis Among Pregnant and Postpartum Women in Guinea-Bissau","status":"NOT_YET_RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2026-02","conditions":"Tuberculosis (TB), Tuberculosis Infection, Latent, Pregnancy","enrollment":720},{"nctId":"NCT07387601","phase":"NA","title":"Effect of Peer-led Educational Intervention on Treatment Outcomes Among Adults With Drug-susceptible Pulmonary Tuberculosis in South Omo and Ari Zone, Southern Ethiopia","status":"NOT_YET_RECRUITING","sponsor":"Bahirdar University","startDate":"2026-02-24","conditions":"to Assess Effect of Peer-led Education","enrollment":250},{"nctId":"NCT04052022","phase":"","title":"Paradoxical Tuberculosis Reactions in Patients Without HIV Infection","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-20","conditions":"Tuberculosis","enrollment":140},{"nctId":"NCT06153069","phase":"PHASE4","title":"Asymptomatic TB With Innovative Modified Short-course Regimens","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-11-21","conditions":"Tuberculosis","enrollment":426},{"nctId":"NCT06498414","phase":"PHASE2, PHASE3","title":"Shorter and Safer Treatment Regimens for Latent TB","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2025-06-10","conditions":"Tuberculosis Infection, Latent","enrollment":1800},{"nctId":"NCT07209761","phase":"PHASE3","title":"A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2025-10-16","conditions":"Pulmonary Tuberculosis","enrollment":532},{"nctId":"NCT03089983","phase":"NA","title":"Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-08-21","conditions":"Opioid Dependence, Addiction, HIV/AIDS","enrollment":316},{"nctId":"NCT07393438","phase":"PHASE2","title":"Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2026-02-21","conditions":"Multidrug-Resistant Tuberculosis, Rifampicin-resistant Tuberculosis, MDR-TB","enrollment":120},{"nctId":"NCT07386912","phase":"","title":"Investigation of the Effects of Oxidized Antigens on the T-Cell Response and the Epigenetic Reprogramming of Neutrophils in Lung Diseases - OXIGENE -","status":"NOT_YET_RECRUITING","sponsor":"Research Center Borstel","startDate":"2026-02-01","conditions":"Asthma, COPD, Bacterial Pneumonia","enrollment":100},{"nctId":"NCT06318416","phase":"PHASE1","title":"Precision Rifampin Trial for Personalized Dosing","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2025-10-01","conditions":"Tuberculosis","enrollment":200},{"nctId":"NCT06585683","phase":"","title":"Post-Trial Tuberculosis Case Finding: A Substudy of CoVPN 3008","status":"COMPLETED","sponsor":"COVID-19 Prevention Network","startDate":"2024-09-13","conditions":"Tuberculosis","enrollment":5694},{"nctId":"NCT05553236","phase":"NA","title":"Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-08-01","conditions":"Drug-resistant Tuberculosis, HIV Coinfection, Cost-Benefit Analysis","enrollment":2500},{"nctId":"NCT07363798","phase":"","title":"Association of Nutrition and T Cell Immune Activity With Disease Progression in Nontuberculous Mycobacterial Pulmonary Disease","status":"NOT_YET_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2026-01","conditions":"Nontuberculous Mycobacterial Pulmonary Disease, Nontuberculous Mycobacterial Lung Disease","enrollment":50},{"nctId":"NCT07303699","phase":"PHASE2","title":"ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD)","status":"RECRUITING","sponsor":"Obafemi Awolowo University Teaching Hospital","startDate":"2026-01-03","conditions":"Pulmonary Tuberculosis (TB)","enrollment":80},{"nctId":"NCT06590428","phase":"NA","title":"Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis","status":"RECRUITING","sponsor":"Albert Einstein College of Medicine","startDate":"2026-03","conditions":"Rifampin-resistant Tuberculosis, Drug-resistant Tuberculosis","enrollment":280},{"nctId":"NCT04165317","phase":"PHASE3","title":"A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2019-12-30","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":1068},{"nctId":"NCT07357844","phase":"","title":"Pediatric Optimal Tuberculosis Treatment Evaluation and Reassessment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-01-03","conditions":"Tuberculosis Disease","enrollment":150},{"nctId":"NCT05411744","phase":"PHASE4","title":"One-month Latent Tuberculosis Treatment for Renal Transplant Candidates","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2022-07-01","conditions":"Latent Tuberculosis, End Stage Renal Disease, Renal Transplant Candidate for Right Kidney","enrollment":25},{"nctId":"NCT06441006","phase":"PHASE2, PHASE3","title":"Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-10-03","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR","enrollment":400},{"nctId":"NCT03500172","phase":"NA","title":"HIV Treatment Retention Interventions for Women Living With HIV (Siyaphambili Study)","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2018-06-22","conditions":"HIV-1 Virologic Response","enrollment":1391},{"nctId":"NCT07332325","phase":"PHASE3","title":"STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis","status":"NOT_YET_RECRUITING","sponsor":"University of Virginia","startDate":"2026-04","conditions":"Sepsis, Tuberculosis","enrollment":344},{"nctId":"NCT03598842","phase":"NA","title":"Tuberculosis - Learning the Impact of Nutrition","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2019-07-12","conditions":"Tuberculosis, Malnutrition, Helminth Infection","enrollment":786},{"nctId":"NCT06845618","phase":"","title":"Blood Tuberculosis DNA Levels to Monitor Tuberculosis Treatment","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","startDate":"2026-02-01","conditions":"Mycobacterium Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Extra-Pulmonary","enrollment":140},{"nctId":"NCT04951986","phase":"PHASE3","title":"Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cape Town","startDate":"2021-08-11","conditions":"Disseminated Tuberculosis, HIV","enrollment":732},{"nctId":"NCT07313995","phase":"NA","title":"Digital Health Intervention to Improve TPT Uptake","status":"NOT_YET_RECRUITING","sponsor":"Arba Minch University","startDate":"2026-01-15","conditions":"Tuberculosis, Pulmonary","enrollment":304},{"nctId":"NCT06214910","phase":"NA","title":"ThiPhiSA: New Pathways to Prevention From Community TB Screening in South Africa","status":"COMPLETED","sponsor":"University of Washington","startDate":"2024-02-20","conditions":"Tuberculosis, HIV I Infection","enrollment":301},{"nctId":"NCT07170735","phase":"","title":"Quantitative Measurement of Plasma and Urine MTB Cell-free DNA Level","status":"NOT_YET_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2026-01-01","conditions":"Tuberculosis","enrollment":85},{"nctId":"NCT07086820","phase":"NA","title":"Window Prophylaxis for Pediatric Tuberculosis Prevention Trial","status":"RECRUITING","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2025-10-27","conditions":"Tuberculosis Infection, Household Contacts, Children","enrollment":647},{"nctId":"NCT03711032","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-24","conditions":"High-risk Non-muscle Invasive Bladder Cancer","enrollment":1397},{"nctId":"NCT04738812","phase":"PHASE3","title":"Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-04-21","conditions":"Tuberculosis, HIV-1-infection, Immuno-Deficiency","enrollment":1330},{"nctId":"NCT06845358","phase":"PHASE1","title":"Safety and Challenge Study of BCG TICE(R) Vaccination to Test Tuberculosis Immunity in Heathy Humans","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-11-26","conditions":"Tuberculosis","enrollment":""},{"nctId":"NCT05590455","phase":"PHASE2","title":"Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2023-04-11","conditions":"Tuberculous Meningitis, HIV I Infection","enrollment":130},{"nctId":"NCT07278453","phase":"NA","title":"TB SCReening Improves Preventive Therapy Uptake in Pregnant Women With HIV","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-06","conditions":"Pregnant HIV Positive Women, HIV, Tuberculosis (TB)","enrollment":1500},{"nctId":"NCT05122767","phase":"PHASE1, PHASE2","title":"Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2023-05-24","conditions":"Tuberculosis, HIV","enrollment":92},{"nctId":"NCT05118490","phase":"PHASE4","title":"Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2023-07-19","conditions":"HIV Seropositivity, Tuberculosis, Household Contact","enrollment":1000},{"nctId":"NCT05609552","phase":"","title":"Biodistribution and Pharmacokinetics of Pretomanid in Tuberculosis Patients Using 18F-Pretomanid PET","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2023-05-22","conditions":"Tuberculosis","enrollment":10},{"nctId":"NCT07077213","phase":"","title":"18F-FAPI-74 in Tuberculosis Patients","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-02","conditions":"Tuberculosis, Pulmonary","enrollment":30},{"nctId":"NCT04919239","phase":"PHASE2","title":"Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB)","status":"COMPLETED","sponsor":"Archivel Farma S.L.","startDate":"2021-09-22","conditions":"Tuberculosis, Pulmonary","enrollment":140},{"nctId":"NCT04240990","phase":"NA","title":"Development of a Diagnostic Prediction Score for Tuberculosis in Hospitalized Children With Severe Acute Malnutrition (TB-Speed SAM)","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2019-11-04","conditions":"Tuberculosis, Severe Acute Malnutrition","enrollment":603},{"nctId":"NCT05455112","phase":"PHASE2","title":"Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis","status":"COMPLETED","sponsor":"Archivel Farma S.L.","startDate":"2022-10-29","conditions":"Tuberculosis, Pulmonary","enrollment":41},{"nctId":"NCT07271225","phase":"NA","title":"Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and Vomiting","status":"RECRUITING","sponsor":"Indonesia University","startDate":"2025-11-05","conditions":"Tuberculosis, Pulmonary","enrollment":58},{"nctId":"NCT05630872","phase":"PHASE2","title":"Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-02-13","conditions":"HIV-associated Tuberculosis","enrollment":30},{"nctId":"NCT07268664","phase":"PHASE3","title":"Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort","status":"NOT_YET_RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2025-12-01","conditions":"Rifampicin Resistant Tuberculosis, Pulmonary Tuberculosis, Tuberculosis","enrollment":120},{"nctId":"NCT04334070","phase":"","title":"Lamprene Multiple Patient Program","status":"AVAILABLE","sponsor":"Novartis Pharmaceuticals","startDate":"","conditions":"Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":""},{"nctId":"NCT03831906","phase":"NA","title":"Impact of Systematic Early Tuberculosis Detection Using Xpert MTB/RIF Ultra in Children With Severe Pneumonia in High Tuberculosis Burden Countries (TB-Speed Pneumonia)","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2019-03-20","conditions":"Tuberculosis, Severe Pneumonia, Covid19","enrollment":2570},{"nctId":"NCT05383742","phase":"PHASE2","title":"Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-12-07","conditions":"Tuberculous Meningitis","enrollment":330},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT06905522","phase":"PHASE3","title":"A PAN-USR TB Multi-Center Trial","status":"RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-06-18","conditions":"Pulmonary Tuberculosis","enrollment":610},{"nctId":"NCT03528694","phase":"PHASE3","title":"Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-05-14","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":1018},{"nctId":"NCT05845112","phase":"","title":"Start Taking Action For TB Diagnosis","status":"COMPLETED","sponsor":"Liverpool School of Tropical Medicine","startDate":"2025-02-28","conditions":"Diagnosis, Tuberculosis","enrollment":14747},{"nctId":"NCT07228702","phase":"PHASE1","title":"Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection","status":"ENROLLING_BY_INVITATION","sponsor":"Vancouver Coastal Health","startDate":"2025-11","conditions":"Non-Tuberculous Mycobacterial (NTM) Pneumonia, Mycobacterium Abscessus Infection","enrollment":1},{"nctId":"NCT06084715","phase":"","title":"The INSTITUT Study Tuberculosis Nutritional Support","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2023-09-07","conditions":"Tuberculosis, Pulmonary, Undernutrition","enrollment":769},{"nctId":"NCT07227779","phase":"PHASE2","title":"B-PaLMZ for TB Meningitis","status":"NOT_YET_RECRUITING","sponsor":"University of Minnesota","startDate":"2026-02-15","conditions":"Tuberculous Meningitis","enrollment":240},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT06418711","phase":"PHASE3","title":"ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension","status":"TERMINATED","sponsor":"Mannkind Corporation","startDate":"2024-09-11","conditions":"MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous","enrollment":132},{"nctId":"NCT05342064","phase":"NA","title":"Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2023-07-11","conditions":"Tuberculosis, HIV Coinfection, Tuberculosis Infection","enrollment":6500},{"nctId":"NCT05671718","phase":"NA","title":"Bring BPaL2Me Trial Comparing Nurse-Led RR-TB Treatment to Physician-Led RR-TB Treatment","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-09-04","conditions":"Drug Resistant Tuberculosis","enrollment":2944},{"nctId":"NCT07213765","phase":"PHASE4","title":"Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease","status":"RECRUITING","sponsor":"Bin Cao","startDate":"2025-07-24","conditions":"Mycobacterium Avium Complex Pulmonary Disease","enrollment":188},{"nctId":"NCT05382312","phase":"PHASE2","title":"Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-07-26","conditions":"Tuberculosis","enrollment":127},{"nctId":"NCT06114628","phase":"PHASE2","title":"Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-01-09","conditions":"Pulmonary Tuberculosis","enrollment":2500},{"nctId":"NCT04734652","phase":"PHASE2","title":"INSTI's For The Management of HIV-associated TB","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2022-02-18","conditions":"HIV/AIDS, Tuberculosis, Pulmonary","enrollment":122},{"nctId":"NCT05220163","phase":"NA","title":"Evaluating the Impact of Computer-assisted X-ray Diagnosis and Other Triage Tools to Optimise Xpert Orientated Community-based Active Case Finding for TB and COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cape Town","startDate":"2022-02-23","conditions":"Tuberculosis, COVID-19, HIV Infections","enrollment":26200},{"nctId":"NCT07191834","phase":"","title":"A Study on the Short - Course Treatment Regimen Containing Pretomanid for Diabetes Mellitus Complicated With Rifampicin - Resistant/Multidrug - Resistant Pulmonary Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Pulmonary Hospital","startDate":"2025-09-30","conditions":"Rifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis, Type 2 Diabetes Mellitus (T2DM), Pretomanid","enrollment":60},{"nctId":"NCT06199921","phase":"PHASE2","title":"ATORvastatin in Pulmonary TUBerculosis","status":"RECRUITING","sponsor":"Obafemi Awolowo University Teaching Hospital","startDate":"2024-01-03","conditions":"Pulmonary Tuberculosis, Tuberculosis, Koch's Disease","enrollment":440},{"nctId":"NCT06665399","phase":"","title":"Observation Alone for Mild Non-Lactational Mastitis","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-09-11","conditions":"Granulomatous Mastitis, Mastitis Chronic","enrollment":57},{"nctId":"NCT02563327","phase":"PHASE3","title":"Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-05-30","conditions":"Tuberculosis","enrollment":53},{"nctId":"NCT03915366","phase":"PHASE2, PHASE3","title":"Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia","status":"COMPLETED","sponsor":"Hospital Universitario 12 de Octubre","startDate":"2020-03-01","conditions":"Pneumonia, HIV/AIDS, Tuberculosis","enrollment":563},{"nctId":"NCT05766267","phase":"PHASE2, PHASE3","title":"Short-course Regimens for the Treatment of Pulmonary Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2023-11-21","conditions":"Tuberculosis, Pulmonary, Tuberculosis Infection","enrollment":288},{"nctId":"NCT07157904","phase":"","title":"Evaluation of PATHFAST-LAM as a Tuberculosis Treatment Monitoring Tool in Kenya","status":"NOT_YET_RECRUITING","sponsor":"Nagasaki University","startDate":"2026-01","conditions":"Tuberculosis, Pulmonary Tuberculoses, Mycobacterium Tuberculosis","enrollment":300},{"nctId":"NCT05557487","phase":"","title":"Taiwan Real-world LDCT Screening Behavior and Outcome Research for High Risk Subjects Based on Health Promotion Administration","status":"RECRUITING","sponsor":"Gee-Chen Chang","startDate":"2022-12-15","conditions":"Lung Cancer, High-Risk Cancer, Smoking","enrollment":6618},{"nctId":"NCT06796647","phase":"","title":"ESAT6/CFP10 Skin Testing for TB Infection in Rheumatologic Patients","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2025-03-19","conditions":"Tuberculosis (TB)","enrollment":100},{"nctId":"NCT07164586","phase":"","title":"Early Detection of Acute Respiratory Failure Using an Intelligent Respiratory Monitoring System","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pernambuco","startDate":"2025-08-18","conditions":"Patients at Risk of Acute Respiratory Failure","enrollment":300},{"nctId":"NCT05412212","phase":"NA","title":"Brief Educational Video for Patients Prescribed LTBI Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kaiser Permanente","startDate":"2022-06-03","conditions":"Latent Tuberculosis","enrollment":1898}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ALOPECIA"},{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"BALANCE DISORDER"},{"count":1,"reaction":"BLOOD PRESSURE ABNORMAL"},{"count":1,"reaction":"CEREBELLAR ISCHAEMIA"},{"count":1,"reaction":"DECREASED IMMUNE RESPONSIVENESS"},{"count":1,"reaction":"DIABETES MELLITUS"},{"count":1,"reaction":"GAIT DISTURBANCE"},{"count":1,"reaction":"HEPATIC LESION"}],"_approvalHistory":[],"publicationCount":5644,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tuberculosis treatment","genericName":"Tuberculosis treatment","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tuberculosis treatment typically involves the use of small molecule inhibitors that target Mycobacterium tuberculosis H37Rv. The exact treatment plan for TB can vary depending on the specific condition being treated, but it often includes a combination of medications.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}